Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

The drug could also have a unique selling point in this indication as results from the phase 3 trial came from Libtayo monotherapy ... who cannot tolerate the side effects.

Regarding safety, solnerstotug remains well tolerated, with no dose-limiting toxicities and most side effects being grade 1 (mild ... All received solnerstotug (3 mg/kg or 15 mg/kg) with Libtayo.